The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImage Scan Holdings Regulatory News (IGE)

Share Price Information for Image Scan Holdings (IGE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.35
Bid: 1.20
Ask: 1.50
Change: 0.00 (0.00%)
Spread: 0.30 (25.00%)
Open: 1.35
High: 1.35
Low: 1.35
Prev. Close: 1.35
IGE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Yearly Report

12 Jun 2014 07:00

RNS Number : 4018J
Image Scan Holdings PLC
12 June 2014
 



Image Scan Holdings plc

Interim report 2014

 

 

12 June 2014

 

IMAGE SCAN HOLDINGS PLC

("Image Scan" or the "Company")

(AIM: IGE)

 

INTERIM RESULTS

Revenue up 57%, reduced overheads

 

Image Scan, the AIM-listed specialist supplier of x-ray screening systems to the security and industrial inspection markets, today announces its interim results for the six months ended 31 March 2014.

 

Financial summary:

· Revenue up 57% to £1,678,000 (2013: £1,072,000)

· Gross profit margin of 31% (2013: 32%) after provision for further losses on the nuclear contract

· Overheads down 22% to £576,000 (2013: £740,000) following the 2013 restructuring exercise

· Loss after taxation of £36,000 (2013: £389,000)

· Period end bank balance of £25,000 (2013: £138,000)

· Current bank balance of £190,000

 

Operational highlights:

· Board realigned and strengthened with appointment of Bill Mawer as Chairman and Chief Executive Officer

· H1 revenue increase based on strong sales across whole security product range

· Delivered a number of multiple unit contracts for the portable FlatScan system

· Repeat sales of standard industrial systems to existing customer

· Confirmed orders of £2.3m having opened the year with £1.2m and booked £1.1m of new orders in the year to date

 

 

Bill Mawer, Chairman and Chief Executive Officer of Image Scan, commented: "These results show positive improvement over the equivalent period in the prior year, and the growth in sales in the core portable X-ray market is particularly encouraging. Maintenance of that growth is dependent, in the short term, on the supply of a newly developed replacement portable x-ray generator, and, in the medium term, on the timely completion of new product development.

 

"Image Scan has a strong brand in its core markets; however, there is a need to accelerate product development in order to drive the business forward, both in terms of the competitive solutions we provide and our geographical reach. Our strategy will focus on supporting targeted growth in our R&D and sales activity with the aim of evolving Image Scan into a business that consistently delivers both top-line growth and bottom line profitability."

 

For further information on the Company, please visit: www.ish.co.uk and for further information on its products, please visit: www.3dx-ray.com

 

Enquiries:

Image Scan Holdings plc

Bill Mawer, Chairman and Chief Executive Officer

Tel: +44 (0) 1509 817 400

ir@ish.co.uk

Cantor Fitzgerald Europe (Nominated Adviser)  

Mark Percy/Rick Thompson

Paul Jewell/David Banks

Tel: +44 (0) 207 894 7000

Yellow Jersey PR Limited

Dominic Barretto

Anna Legge

Tel: +44 (0) 7768 537 739

 

 

 

 

 

Chairman's statement

 

 

Introduction

I am pleased to report my first set of results as Chairman and Chief Executive Officer of Image Scan. Image Scan remains focused on the development and commercialisation of market leading real-time x-ray solutions for use in the global security and industrial inspection markets. The Company's Security portfolio includes the Axis range of conveyor systems; the FlatScan range of portable bomb and suspect package detection systems; and SVXi, a small vehicle inspection system. The Industrial Inspection solutions include the MDXi product range, cabinet x-ray systems for laboratories and production lines.

 

Financial results

I am pleased to report that revenue for the six months has increased by 57% to £1,678,000 (2013: £1,072,000) based on strong sales across the whole security product portfolio. The gross margin of 31% (2013: 32%) reflected two significant security contracts which were subject to highly competitive tendering processes and the recognition of a further £30,000 (2013: £112,000) of losses against the nuclear contract.

 

Following the restructuring exercise carried out in May 2013, the comparative overheads for the period were down by 22% to £576,000 (2013: £740,000). As a result, the Company has made a loss after tax of £36,000 (2013: £389,000). The loss per share was 0.05p (2013: 0.5p).

 

The cash position as at the end of the period was £25,000 (2013: £138,000). The Company has an agreed £100,000 overdraft facility with the Royal Bank of Scotland. The current bank balance is £190,000.

 

Overview

Security accounted for 85% of total sales. Security revenue in the period was £1,427,000 (2013: £546,000) with increased levels of sales reported against each of the conveyor, portable and vehicle screening product ranges. First half sales of both the conveyor and portable products included a number of multiple unit contracts.

 

Industrial revenue of £251,000 (2013: £526,000) comprised 15% of total revenue and included the sale of a cabinet x-ray system to an existing customer and further deliverables on the nuclear contract. The nuclear customer has accepted delivery of the system and the final phases relate to installation, commissioning and training at the customer's site. Key software engineering resources previously engaged on this contract have now been refocused on the development of the core product range.

 

Subsequent to the period end, the following Board appointments were made to strengthen the technology lead and provide greater strategic focus:

o Bill Mawer, as Chairman and Chief Executive Officer, who has 13 years' experience with Smiths Detection and is a specialist in product development and market strategy; and

o Dr Richard Leaver, as Non-Executive Director, who has extensive international experience of developing and sustaining value in technology-rich growth businesses at all stages of investment.

 

Outlook

The Company has total confirmed orders in the year to date of £2.3m, having started the year with an opening order book of £1.2m and secured new orders of £1.1m. All outstanding orders are deliverable in the current financial year. Whilst the revenue in the first half of the year was on target, performance in the second half will be reliant on the supply of a newly developed portable generator to replace the existing system which is no longer available.

 

 As a result of the commitment of a limited resource base to the nuclear contract over the last three years the Company's R&D activities have been restricted to modest incremental development. The Board recognises the need to expand the product range and has been reviewing what additional inputs are required to accelerate product development. The strategy that I have been developing since becoming involved with the Company in late 2013 will be to support carefully targeted growth in R&D and sales activity to include the following projects:

o complete the renewal of the existing portable x-ray product range to restore its competitive edge;

o extend the portable range to include both higher and lower-end solutions, giving the Company, for the first time, a competitive product in each market segment;

o co-development, with an experienced partner, of a highly competitive range of checkpoint x-ray systems to replace the current Axis products;

o recruit an additional security sales manager and development of the sales network to provide geographical coverage of all important security x-ray markets; and

o recruit a dedicated sales manager for industrial sales, in order to expand the Company's potentially valuable market position.

 

Image Scan has a strong brand in its core markets and loyal distributors and customers. Over-commitment of its limited R&D resources in recent years has caused a decline in competitiveness which is now being addressed. The staff at Image Scan are enthusiastic, dedicated and creative and on behalf of my fellow Board members and shareholders, I would like to formally thank our staff for their contribution during this period.

 

 

Bill Mawer

Chairman and Chief Executive Officer

12 June 2014

 

 

 

Consolidated income statement

for the six months ended 31 March 2014

 

Six months ended

Six months ended

Year ended

31 March 2014

31 March 2013

30 September 2013

(Unaudited)

(Unaudited and restated)

(Audited)

Note

£'000

£'000

£'000

Revenue

1,678

1,072

2,538

Cost of sales

2

(1,161)

(731)

(1,587)

Gross profit

517

341

951

Administrative expenses

2

(576)

(740)

(1,293)

Operating loss

(59)

(399)

(342)

Finance revenue

-

-

-

Loss before taxation

(59)

(399)

(342)

Taxation

23

10

45

Loss for the period

(36)

(389)

(297)

 

Pence

Pence

Pence

Earnings per share

Basic and diluted loss per share

4

(0.05)

(0.50)

(0.39)

 

 

 

Consolidated statement of changes in equity

for the six months ended 31 March 2014

 

 

Six months to

Six months to

Year to

31 March 2014

31 March 2013

30 September 2013

(Unaudited)

(Unaudited)

(Audited)

Note

£'000

£'000

£'000

Opening equity shareholders' funds

677

977

977

Share-based payments

5

-

-

(3)

Loss attributable to equity shareholders

(36)

(390)

(297)

641

587

677

 

 

 

Consolidated balance sheet

as at 31 March 2014

 

As at

As at

As at

31 March 2014

31 March 2013

30 September 2013

(Unaudited)

(Unaudited)

(Audited)

£'000

£'000

£'000

Non-current assets

Plant and equipment

16

31

22

Intangible assets

-

-

-

16

31

22

Current assets

Inventories

352

650

458

Trade and other receivables

651

240

1,120

Cash and cash equivalents

25

138

12

Current tax asset

59

-

36

1,087

1,028

1,626

Total assets

1,103

1,059

1,648

Current liabilities

Trade and other payables

440

426

928

Non-current liabilities

Provisions for liabilities and charges

22

46

43

Total liabilities

462

472

971

Net assets

641

587

677

Equity

Share capital

763

763

763

Share premium account

7,501

7,501

7,501

Retained earnings

(7,623)

(7,677)

(7,587)

Equity shareholders' funds

641

587

677

 

This interim financial information was approved by the Board of Directors on 12 June 2014.

 

 

Bill Mawer

Chairman and Chief Executive Officer

 

 

 

 

Consolidated cash flow statement

for the six months ended 31 March 2014

 

Six months to

Six months to

Year to

31 March 2014

31 March 2013

30 September 2013

(Unaudited)

(Unaudited)

(Audited)

£'000

£'000

£'000

Cash flows from operating activities

Operating loss

(59)

(400)

(342)

Adjustments for:

Depreciation

7

11

21

Transfer of fixed assets to stock

2

-

4

Decrease/(increase) in inventories

106

(237)

(46)

Decrease in trade and other receivables

469

548

2

(Decrease)/increase in trade and other payables

(509)

60

224

Share-based payment charge

-

-

(2)

Corporation tax recovered

-

85

85

Net cash inflow/(outflow) from operating activities

16

67

(54)

Cash flows from investing activities

Purchase of property, plant and equipment

(3)

(3)

(8)

Net cash used in investing activities

(3)

(3)

(8)

Net increase/(decrease) in cash and cash equivalents

13

64

(62)

Cash and cash equivalents at beginning of period

12

74

74

Cash and cash equivalents at end of period

25

138

12

 

 

 

 

 

Notes to the unaudited interim financial statements

for the six months ended 31 March 2014

 

1 Basis of preparation

The interim financial statements, which are unaudited, have been prepared on the basis of the accounting policies expected to apply for the financial year to 30 September 2014 and in accordance with recognition and measurement principles of International Financial Reporting Standards (IFRSs) as endorsed by the European Union. The accounting policies applied in the preparation of these interim financial statements are consistent with those used in the financial statements for the year ended 30 September 2013.

 

The interim financial statements do not include all of the information required for full annual financial statements and do not comply with all the disclosures in IAS 34 'Interim Financial Reporting'. Accordingly, whilst the interim statements have been prepared in accordance with IFRS, they cannot be construed as being in full compliance with IFRSs.

 

The financial information for the year ended 30 September 2013 does not constitute the full statutory accounts for that period. The Annual Report and Financial Statements for the year ended 30 September 2013 have been filed with the Registrar of Companies. The independent Auditor's Report on the Report and Financial Statements for the year ended 30 September 2013 was unqualified, did not draw attention to any matters by way of emphasis, and did not contain a statement under 498(2) or 498(3) of the Companies Act 2006.

 

2 Losses on nuclear contract

In the 2013 interim results, the loss of £112,000 on the nuclear contract was reported as an exceptional item within administrative expenses. This was subsequently accounted for as cost of sales in the full statutory accounts for the year ended 2013. The comparative 2013 numbers in the 2014 interim results reflect this same treatment, giving cost of sales of £731,000 and administrative expenses of £740,000 (previously reported as £619,000 and £852,000 respectively).

 

3 Going concern

The interim financial information has been prepared on a going concern basis, which assumes that the Company will have adequate resources to continue in operational existence for the foreseeable future.

 

4 Earnings per share ('EPS')

Basic earnings per ordinary share is based on the loss on ordinary activities after taxation of £36,000 and on 76,267,932 ordinary shares in issue throughout the period.

 

IAS 33 requires presentation of diluted EPS when a company could be called upon to issue shares that would decrease net profit or increase net loss per share. Earnings or loss per share would not be affected by the exercise of out-of-the-money options since it is inappropriate to assume that option holders would act irrationally. Accordingly as there are no other diluting future share issues, diluted EPS equals basic EPS.

 

5 IFRS 2 'Share-based payments'

Operating expenses includes a charge of £nil (2013: £nil) after valuation of the Company's employee share option schemes in accordance with IFRS 2. Under this standard, the fair value of the options at the grant date is spread over the vesting period. These items have been added back in the consolidated statement of changes in equity.

 

6 Additional copies

Further copies of the 2014 interim report are available on the Company's website, www.ish.co.uk, and from the Company's registered office, 16-18 Hayhill Industrial Estate, Sileby Road, Barrow-upon-Soar, Leicestershire LE12 8LD.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR ZMGMVDMNGDZM
Date   Source Headline
30th Apr 20247:00 amRNSInterim Results
29th Apr 20247:00 amRNSInitial c£300k order for new Portable X-Ray System
12th Mar 20247:00 amRNSLaunch of AXIS-CXi Cabinet with AI Software
28th Feb 20242:48 pmRNSResult of AGM
28th Feb 20247:00 amRNSTrading Statement
26th Jan 20241:50 pmRNSHolding(s) in Company
18th Jan 20241:28 pmRNSHolding(s) in Company
11th Jan 20243:06 pmRNSHolding(s) in Company
9th Jan 202412:46 pmRNSNotice of AGM & Posting of Annual Report
9th Jan 202412:00 pmRNSHolding(s) in Company
22nd Dec 20231:30 pmRNSHolding(s) in Company
12th Dec 20237:00 amRNSFinal Results
10th Oct 20237:00 amRNSTrading Update
11th Sep 20237:00 amRNS2023 orders to over 30 countries
4th Jul 20237:00 amRNSHolding(s) in Company
26th Apr 20237:00 amRNSInterim Results
13th Mar 20239:34 amRNSHolding(s) in Company
28th Feb 20233:03 pmRNSResult of AGM
28th Feb 20237:00 amRNSTrading Statement
10th Feb 20231:26 pmRNSHolding(s) in Company
26th Jan 202312:09 pmRNSDirector/PDMR Shareholding
18th Jan 20238:52 amRNSPosting of annual report and notice of AGM
17th Jan 20233:23 pmRNSImage Scan makes first sale of new product
23rd Dec 202211:54 amRNSDirector/PDMR Shareholding
14th Dec 20224:14 pmRNSAppointment of Director
13th Dec 20224:25 pmRNSHolding(s) in Company
13th Dec 20227:00 amRNSFinal Results
9th Dec 20227:00 amRNSNotice of Results
6th Oct 20227:00 amRNSTrading Update
1st Aug 20224:10 pmRNSHolding(s) in Company
25th May 20227:00 amRNSBoard Changes
27th Apr 20227:00 amRNSInterim Results
3rd Mar 20227:00 amRNSNew Industrial Customer
22nd Feb 20223:03 pmRNSResult of AGM
22nd Feb 20227:00 amRNSTrading Statement
20th Jan 202211:53 amRNSPosting of Accounts & AGM Notice
12th Jan 20227:00 amRNSLaunch of new portable X-ray system
10th Dec 20219:05 amRNSInvestor Presentation
7th Dec 202110:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
7th Dec 20217:00 amRNSFinal Results
10th Nov 20211:16 pmRNSAppointed global distributor for Serstech AB
10th Nov 20217:00 amRNSPortable x-ray sale to US Federal Agency
3rd Nov 20217:00 amRNSPre-Close Trading Update
27th Oct 20219:32 amRNSDirector Declaration
13th Sep 20217:00 amRNSTrading Update – New Orders
17th Jun 20217:00 amRNSFirst portable X-Ray sale to Australia
28th Apr 202110:03 amRNSInterim Report - Replacement
28th Apr 20217:00 amRNSNew order
28th Apr 20217:00 amRNSInterim Report
23rd Feb 202111:18 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.